Vanguard Global Advisers
TRVI icon

Vanguard Global Advisers’s Trevi Therapeutics TRVI Stock Holding History

Vanguard Global Advisers’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Buy
64,278
+5,378
+9% +$78.2K ﹤0.01% 1628
2026
Q1 		$703K Buy
+58,900
New +$659K ﹤0.01% 1857

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Global Advisers's TRVI Position: Q2 2026 in Review

Vanguard Global Advisers increased its Trevi Therapeutics (TRVI) stake by 9.1% in Q2 2026, buying an estimated $78.2K and bringing the position to 64,278 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Vanguard Global Advisers first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Vanguard Global Advisers held 64,278 shares of Trevi Therapeutics worth $1.2M as of Q2 2026.
  • Vanguard Global Advisers bought 5,378 Trevi Therapeutics shares in Q2 2026, an estimated $78.2K.
  • Trevi Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1628 holding.
  • Vanguard Global Advisers first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.